Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder (CFS:M)
Chronic Fatigue Syndrome
About this trial
This is an interventional treatment trial for Chronic Fatigue Syndrome focused on measuring myalgic encephalopathy, chronic fatigue syndrome, post viral infection, fatigue, muscle pain, unrefreshing sleep, fuzzy thought, poor memory, forgetfulness
Eligibility Criteria
Inclusion Criteria:
Subjects must meet the criteria for CFS of the US Centers for Disease Control and Prevention (CDC), which requires persistent, unexplained fatigue for at least 6 months, concurrent with four of the following:
- impaired memory/concentration
- sore throat, new headaches
- unrefreshing sleep, muscle pain
- multi-joint pain
- tender lymph nodes
- post-exertional malaise
As well, due to the frequency of visits subjects must currently reside in the greater New York area.
Exclusion Criteria:
- shortness of breath
- heart disease
- high blood pressure
- other severe chronic illnesses
- clinical depression
- generalized anxiety disorder
- insomnia
- inflammatory arthritis
- anemia
- hypothyroidism
- other conditions associated with significant fatigue
- history of alcohol, tobacco, or drug abuse
Sites / Locations
- Columbia University Department of Clinical Genetics
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Nutraceuticals
Placebo
Subjects will receive a combination of 4 nutraceuticals (CoEnzyme Q10, acetyl-L-carnitine, alpha-lipoic acid, docosahexaenoic acid (DHA)) and a multivitamin.